Global Peptides Biosimilars Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Peptides Biosimilars Revenue
• 1.4 Market 2
  • 1.4.1 Global Peptides Biosimilars Market Size Growth Rate 2: 2020 VS 2026
  • 1.4.2 Glucagon
  • 1.4.3 Calcitonin
• 1.5 Market by Application
  • 1.5.1 Global Peptides Biosimilars Market Share 7: 2020 VS 2026
  • 1.5.2 Oncology
  • 1.5.3 Chronic Diseases
  • 1.5.4 Autoimmune Diseases
  • 1.5.5 Blood Disorders
  • 1.5.6 Growth Hormone Deficiency
  • 1.5.7 Infectious Diseases
  • 1.5.8 Other Diseases
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Peptides Biosimilars Market Perspective (2015-2026)
• 2.2 Global Peptides Biosimilars Growth Trends by Regions
  • 2.2.1 Peptides Biosimilars Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Peptides Biosimilars Historic Market Share by Regions (2015-2020)
  • 2.2.3 Peptides Biosimilars Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Peptides Biosimilars Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Peptides Biosimilars Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Peptides Biosimilars Players by Market Size
  • 3.1.1 Global Top Peptides Biosimilars Players by Revenue (2015-2020)
  • 3.1.2 Global Peptides Biosimilars Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Peptides Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Peptides Biosimilars Market Concentration Ratio
  • 3.2.1 Global Peptides Biosimilars Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Peptides Biosimilars Revenue in 2019
• 3.3 Peptides Biosimilars Key Players Head office and Area Served
• 3.4 Key Players Peptides Biosimilars Product Solution and Service
• 3.5 Date of Enter into Peptides Biosimilars Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size 2 (2015-2026)

• 4.1 Global Peptides Biosimilars Historic Market Size 2 (2015-2020)
• 4.2 Global Peptides Biosimilars Forecasted Market Size 2 (2021-2026)

5 Market Size 7 (2015-2026)

• 5.1 Global Peptides Biosimilars Market Size 7 (2015-2020)
• 5.2 Global Peptides Biosimilars Forecasted Market Size 7 (2021-2026)

6 North America

• 6.1 North America Peptides Biosimilars Market Size (2015-2020)
• 6.2 Peptides Biosimilars Key Players in North America (2019-2020)
• 6.3 North America Peptides Biosimilars Market Size 2 (2015-2020)
• 6.4 North America Peptides Biosimilars Market Size 7 (2015-2020)

7 Europe

• 7.1 Europe Peptides Biosimilars Market Size (2015-2020)
• 7.2 Peptides Biosimilars Key Players in Europe (2019-2020)
• 7.3 Europe Peptides Biosimilars Market Size 2 (2015-2020)
• 7.4 Europe Peptides Biosimilars Market Size 7 (2015-2020)

8 China

• 8.1 China Peptides Biosimilars Market Size (2015-2020)
• 8.2 Peptides Biosimilars Key Players in China (2019-2020)
• 8.3 China Peptides Biosimilars Market Size 2 (2015-2020)
• 8.4 China Peptides Biosimilars Market Size 7 (2015-2020)

9 Japan

• 9.1 Japan Peptides Biosimilars Market Size (2015-2020)
• 9.2 Peptides Biosimilars Key Players in Japan (2019-2020)
• 9.3 Japan Peptides Biosimilars Market Size 2 (2015-2020)
• 9.4 Japan Peptides Biosimilars Market Size 7 (2015-2020)

10 Key Players Profiles

• 10.1 Sandoz
  • 10.1.1 Sandoz Company Details
  • 10.1.2 Sandoz Business Overview
  • 10.1.3 Sandoz Peptides Biosimilars Introduction
  • 10.1.4 Sandoz Revenue in Peptides Biosimilars Business (2015-2020))
  • 10.1.5 Sandoz Recent Development
• 10.2 Pfizer
  • 10.2.1 Pfizer Company Details
  • 10.2.2 Pfizer Business Overview
  • 10.2.3 Pfizer Peptides Biosimilars Introduction
  • 10.2.4 Pfizer Revenue in Peptides Biosimilars Business (2015-2020)
  • 10.2.5 Pfizer Recent Development
• 10.3 Teva Pahrmaceutical
  • 10.3.1 Teva Pahrmaceutical Company Details
  • 10.3.2 Teva Pahrmaceutical Business Overview
  • 10.3.3 Teva Pahrmaceutical Peptides Biosimilars Introduction
  • 10.3.4 Teva Pahrmaceutical Revenue in Peptides Biosimilars Business (2015-2020)
  • 10.3.5 Teva Pahrmaceutical Recent Development
• 10.4 Celltrion
  • 10.4.1 Celltrion Company Details
  • 10.4.2 Celltrion Business Overview
  • 10.4.3 Celltrion Peptides Biosimilars Introduction
  • 10.4.4 Celltrion Revenue in Peptides Biosimilars Business (2015-2020)
  • 10.4.5 Celltrion Recent Development
• 10.5 Biocon
  • 10.5.1 Biocon Company Details
  • 10.5.2 Biocon Business Overview
  • 10.5.3 Biocon Peptides Biosimilars Introduction
  • 10.5.4 Biocon Revenue in Peptides Biosimilars Business (2015-2020)
  • 10.5.5 Biocon Recent Development
• 10.6 Amgen
  • 10.6.1 Amgen Company Details
  • 10.6.2 Amgen Business Overview
  • 10.6.3 Amgen Peptides Biosimilars Introduction
  • 10.6.4 Amgen Revenue in Peptides Biosimilars Business (2015-2020)
  • 10.6.5 Amgen Recent Development
• 10.7 Samsung Biologics
  • 10.7.1 Samsung Biologics Company Details
  • 10.7.2 Samsung Biologics Business Overview
  • 10.7.3 Samsung Biologics Peptides Biosimilars Introduction
  • 10.7.4 Samsung Biologics Revenue in Peptides Biosimilars Business (2015-2020)
  • 10.7.5 Samsung Biologics Recent Development
• 10.8 Mylan
  • 10.8.1 Mylan Company Details
  • 10.8.2 Mylan Business Overview
  • 10.8.3 Mylan Peptides Biosimilars Introduction
  • 10.8.4 Mylan Revenue in Peptides Biosimilars Business (2015-2020)
  • 10.8.5 Mylan Recent Development
• 10.9 Dr. Reddy's Laboratories
  • 10.9.1 Dr. Reddy's Laboratories Company Details
  • 10.9.2 Dr. Reddy's Laboratories Business Overview
  • 10.9.3 Dr. Reddy's Laboratories Peptides Biosimilars Introduction
  • 10.9.4 Dr. Reddy's Laboratories Revenue in Peptides Biosimilars Business (2015-2020)
  • 10.9.5 Dr. Reddy's Laboratories Recent Development
• 10.10 Stada Arzneimittel AG
  • 10.10.1 Stada Arzneimittel AG Company Details
  • 10.10.2 Stada Arzneimittel AG Business Overview
  • 10.10.3 Stada Arzneimittel AG Peptides Biosimilars Introduction
  • 10.10.4 Stada Arzneimittel AG Revenue in Peptides Biosimilars Business (2015-2020)
  • 10.10.5 Stada Arzneimittel AG Recent Development

11 Analyst's Viewpoints/Conclusions

12 Appendix

• 12.1 Research Methodology
  • 12.1.1 Methodology/Research Approach
  • 12.1.2 Data Source
• 12.2 Disclaimer